Posts by William T. Curry, MD
-
Review: The Role of Antibody-Based Therapies in Neuro-Oncology
Rishab Ramapriyan, William T. Curry, MD, Bryan D. Choi, MD, PhD, and colleagues describe the antibody-based therapies being used to treat glioblastoma and other central nervous system tumors, with special attention to the challenges of blood–brain barrier penetration and tumor-derived immunosuppression.
-
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma
Massachusetts General Hospital researchers have developed TanCART, the first chimeric antigen receptor T cell that targets EGFRvIII and IL-13R?2 simultaneously, and found it was effective in vitro and in murine models of heterogeneous glioblastoma, including patient-derived xenografts.
-
Designing Leading-Edge Immunotherapy for Brain Cancer
New immunotherapy for brain cancer tackles the barrier of tumor heterogeneity using a home-grown combination of CAR T-cell therapy and bispecific antibodies.
-
Review: Implications of IDH Mutations for Success of Glioma Immunotherapy
Neuroscience researchers at Massachusetts General Hospital recently reviewed the latest data on the tumor immune microenvironment of IDH-mutant glioma, the role of 2-hydroxyglutarate as a regulator of glioma immune evasion, and novel immunotherapeutic strategies that are being investigated in early clinical trials.
-
Immunotherapies to Treat Glioblastoma
William T. Curry, MD, co-director of Mass General Neuroscience and director of Neurosurgical Oncology in the Department of Neurosurgery at Massachusetts General Hospital, discusses a four-center trial studying the use of poliovirus to treat malignant brain tumors.
-
Case Reports: Mapping of the Thalamocortical Tract in Asleep Craniotomies
Mirela V. Simon, MD, MSc, of the Department of Neurology, William T. Curry, MD, of the Department of Neurosurgery, and colleagues have conducted the first successful electrophysiologic mapping of the thalamocortical tract during supratentorial surgery under general anesthesia in humans.
-
Endonasal Surgery and COVID-19 Protections for Surgeons
William T. Curry, MD, of Massachusetts General Hospital Neuroscience, discusses the collaboration with colleagues at Mass Eye and Ear to create protective equipment to shield neurosurgeons during skull-base procedures.
-
Endonasal Surgery Using High-Speed Drill Puts Health Care Team at Risk of COVID-19
High-speed drilling appears to be the single greatest risk factor for potentially infectious aerosolization of new coronavirus during endonasal surgery, even when activated for only several seconds.
-
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape
A dual-antigen approach to immunotherapy for glioblastoma, pioneered at Massachusetts General Hospital, addresses antigenic heterogeneity and may have applications for treating other types of solid tumors.
-
Using Immunotherapy to Treat Brain Tumors
In this video, William Curry, MD, discusses advancements in immunotherapy to target brain tumors. In clinical trials, he has seen the safety and strong immune activity of vaccinating patients with their own tumor cells, which has made him optimistic about the future of treatment for patients with brain tumors.
-
Brain Infusion of Genetically Modified Poliovirus Is Used to Treat Glioblastoma
A phase II trial kicked off at Massachusetts General Hospital involving multiple departments and research institutes are utilizing oncolytic viruses to treat glioblastomas.
-
Triple Immunotherapy Completely Eradicates Glioma in Animal Models
Researchers at Massachusetts General Hospital found that combining a PD-1 inhibitor with whole tumor cell vaccination and agonist anti-OX40 antibody in a glioma animal model cured all animals and resulted in long-term survival—even after glioma rechallenge.
-
The Survival Advantage: How the Intraoperative Neurophysiology Monitoring Unit at Mass General Lowers Surgical Risk and Improves Prognosis
The Intraoperative Neurophysiologic Monitoring and Mapping (IONM) unit at Massachusetts General Hospital has been a driving force behind increased surgical success with reduced neurological complications.
-
Specialized Admission Pathway Improves Care of Patients with Single Brain Mass
Implementation of an admission and evaluation protocol at Massachusetts General Hospital by a multidisciplinary team streamlined the care of patients with a new single brain mass, significantly reducing time to surgery and length of stay with no effect on the readmission rate.
-
The Mass General Neurosurgery Mission
Researchers from the Department of Neurosurgery at Massachusetts General Hospital discuss their collaborative work in clinical and translational research.
-
Surgery May Not Improve Survival After First Documented Progression of Glioblastoma
After controlling for several potentially confounding factors, neurosurgeons at Massachusetts General Hospital found that resection of progressive glioblastoma is not significantly associated with prolonged post-progression survival, even if gross total resection is achieved.
-
Sense of Taste Can Be Affected After Endonasal Resection of Olfactory Groove Meningioma
As they accumulate experience with EETAs of olfactory groove meningiomas, neurosurgeons at Mass General have twice encountered a previously unreported complication.
-
Surviving Gliomas Through Antibodies and Vaccination
Immunotherapy for glioma is under active investigation, but tumor-associated immunosuppression is a major obstacle. A Mass General team studied an investigational monoclonal antibody in mice with glioma, alone and in combination with tumor cell vaccination.
Biography
Dr. William Curry is a graduate of Harvard College, attended Cornell University Medical College in New York City and trained in Neurosurgery at Massachusetts General Hospital. He has been on the neurosurgical faculty at Mass General since 2004. He is a national leader in the neurosurgical care of patients with tumors of the brain, skull-base, and spine. He is highly skilled in both open and endoscopic/minimally invasive techniques and is known for his ability to handle the most advanced surgical challenges. Dr. Curry leads and participates in multiple clinical trials for patients with brain tumors and is particularly interested in the development of cellular and immune-based therapies for malignant tumors. He is an integral part of the Pappas Center for Neuro-oncology, the Mass General/Mass Eye and Ear Cranial Base Center, and the Harris Chordoma Center at Mass General.
Stephen E. and Catherine Pappas Center for Neuro-Oncology at Mass General
The Stephen E. and Catherine Pappas Center for Neuro-Oncology offers the most advanced care for patients with brain tumors and nervous system tumors.
